Skip to main content

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Written by Customer Service on . Posted in Public Companies.

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial

PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET).

The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago. Dr. Rubin will provide expert insights into the evolving treatment landscape for ulcerative colitis (UC) and discuss expectations for Abivax’s ABTECT Phase 3 trial evaluating obefazimod in adults with moderately to severely active UC. He will also explore obefazimod’s potential to address critical unmet medical needs in UC treatment.

Following the presentation, attendees will have the opportunity to participate in a live Q&A session with Dr. Rubin and Abivax’s management team.

Event Details:

Date: Monday, March 17, 2025

Time: 9:00 a.m. EDT | 2:00 p.m. CET

Format: Virtual webcast

Registration Details:

To register for the webcast and access further event details, please click on this link https://lifescievents.com/event/abivax-3/.  

About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.